SCHEMBL3554081

SCHEMBL3554081

CCCc1ccc(S(=O)(=O)Nc2ccc(OCCOc3ccc(C(=O)O)cc3)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
WDR5 P61964 1/20 0.58
GFER P55789 1/20 0.58
TDP1 Q9NUW8 2/20 0.57
FABP4 P15090 1/20 0.55
LIMK2 P53671 1/20 0.55
POLB P06746 2/20 0.55
KMT2A Q03164 3/20 0.53
MAPT P10636 2/20 0.53
MEN1 O00255 2/20 0.53
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
HTT P42858 1/20 0.52
ALDH1A1 P00352 1/20 0.50
TP53 P04637 1/20 0.50
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3551452 0.93 SMN1; SMN2 (0.63) LMNASMN1; SMN2WDR5GFERTDP1
SCHEMBL3554413 0.93 SMN1; SMN2 (0.65) LMNASMN1; SMN2WDR5GFERTDP1
SCHEMBL3564489 0.91 GFER (0.60) LMNASMN1; SMN2WDR5GFERTDP1
SCHEMBL3562032 0.90 SMN1; SMN2 (0.71) LMNASMN1; SMN2WDR5GFERTDP1
SCHEMBL31681289 0.90 CA12 (0.62) LMNASMN1; SMN2WDR5GFERFABP4
SCHEMBL3554401 0.89 CA12 (0.61) LMNASMN1; SMN2WDR5GFERFABP4
SCHEMBL3555882 0.85 GFER (0.79) LMNASMN1; SMN2WDR5GFERTDP1
SCHEMBL3559760 0.85 HDAC1 (0.64) LMNASMN1; SMN2WDR5GFERTDP1
SCHEMBL3556211 0.85 TDP1 (0.59) LMNAWDR5TDP1FABP4LIMK2
SCHEMBL3560203 0.85 TDP1 (0.54) LMNASMN1; SMN2WDR5TDP1LIMK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 LMNA 2120/4885SMN1; SMN2 4522/4885WDR5 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.